Neoviderm Skin Emulsion in the Prevention of Radiation Dermatitis

A Phase II Study Designed to Evaluate the Value of Neoviderm Skin Emulsion in the Prevention of Radiation Dermatitis for Patients Undergoing External Radiation Therapy

Status

Terminated

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01701466

Enrollment

Registered

2012-10-05

Start date

2011-12-31

Completion date

Unknown

Last updated

2015-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Head and Neck Cancer

Keywords

Patients, with

Brief summary

The purpose of this study is to determine whether NeoVIDERM is effective at preventing radiation dermatitis in patients receiving external beam radiation therapy to the head and neck or breast areas.

Interventions

OTHERAveeno cream

Twice a day

OTHERFlamazine cream

Twice a day, when there is dry desquamation

OTHERNeoVIDERM cream

Three times a day

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

For patients receiving radiation to the breast 1. Patients receiving a dose of at least 50 Gy in 25 fractions with concomitant chemotherapy or treated with the McGill technique. 2. Patients able to understand and sign an informed consent form. 3. Patients that do not have active connective tissue disorders. 4. Patients 18 years or older. 5. Patients that did not receive any previous radiation. 6. Patients that do not have any known allergy to any ingredients of the NeoVIDERM cream 7. Patients need to be able to apply the creams themselves or have help with applying the creams. Inclusion criteria: For patients receiving radiation to the head and neck 1. Patients receiving radiotherapy on fields that include both sides of the neck 2. Patients able to understand and sign an informed consent form. 3. Patients that do not have active connective tissue disorders. 4. Patients 18 years or older. 5. Patients that did not receive any previous radiation. 6. Patients that do not have any known allergy to any ingredients of the NeoVIDERM cream 7. Patients need to be able to apply the creams themselves or have help with applying the creams.

Exclusion criteria

For patients receiving radiation to the breast or the head and neck 1. Patients that have a type V or type VI skin type according to the Fitzpatrick scale (because these patients will likely have less radiodermatitis and if they do, it will be harder to evaluate it). The Fitzpatrick Scale: * Type I (scores 0-7) White; very fair; freckles. Always burns, never tans * Type II (scores 8-16) White; fair. Usually burns, tans with difficulty * Type III (scores 17-25) Beige; very common. Sometimes mild burn, gradually tans * Type IV (scores 25-30) Beige with a brown tint; typical Mediterranean Caucasian skin. Rarely burns, tans with ease * Type V (scores over 30) Dark brown. Very rarely burns, tans very easily * Type VI Black. Never burns, tans very easily 2. Allergic to any ingredient in Neoviderm cream

Design outcomes

Primary

Measure	Time frame	Description
Maximum skin toxicity	7 weeks post beginning of radiation treatments	The objective of this study is to determine the occurrence and degree of acute skin toxicity in patients receiving radical radiation therapy with preventive application of neoVIDERM compared to patients treated with institutional standard skin care.

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026